

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1. (Currently Amended) A method of generating a mucosal immune response an IgA antibody response specific for an antigen at a mucosal surface of a vertebrate subject in need thereof, said method comprising (1) delivering a particulate vaccine composition into or across the skin of a vertebrate said subject using a transdermal delivery technique and (2) coadministering an adjuvant composition to said subject, wherein (a) the vaccine composition comprises an antigen or a nucleic acid encoding said antigen, (b) the antigen is derived or obtained from a pathogen that enters said subject's body via a mucosal surface, and (c) the adjuvant composition comprises (i) an oligonucleotide containing a CpG motif and (ii) an ADP-ribosylating toxin.
2. (Original) The method of claim 1 wherein the particulate vaccine composition is delivered using a needleless syringe powder injection device.
3. (Original) The method of claim 1 wherein the mucosal immune response is specific for the antigen.
- 4.-5. (Canceled)
6. (Original) The method of claim 1 wherein the antigen is a viral antigen.
7. (Original) The method of claim 1 wherein the antigen is a bacterial antigen.
- 8.-9. (Canceled)
10. (Currently Amended) The method of claim [[9]] 1 wherein the adjuvant composition is particulate.

11. (Original) The method of claim 10 wherein the particulate adjuvant composition is delivered into or across the subject's skin using a transdermal delivery technique.
12. (Currently Amended) The method of claim [[9]] 1 wherein the vaccine composition and the adjuvant composition are administered to the same site in the subject.
13. (Currently Amended) The method of claim [[9]] 1 wherein the vaccine composition and the adjuvant composition are administered concurrently.
14. (Original) The method of claim 13 wherein the vaccine composition and the adjuvant composition are combined to provide a single composition.
15. (Original) The method of claim 14 wherein the vaccine composition is administered to the subject from a needleless syringe powder injection device.
- 16.-20. (Canceled)
21. (Currently Amended) The method of claim [[20]] 1 wherein the adjuvant composition comprises a cholera toxin.
22. (Currently Amended) The method of claim [[20]] 1 wherein the adjuvant composition comprises a combination of two or more adjuvants.
23. (Original) The method of claim 22 wherein the adjuvant composition comprises a cholera toxin and an oligonucleotide containing a CpG motif.
- 24.-35. (Canceled)